clinical trial · NCT07011342
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
Hackensack Meridian Health·N/A·recruiting·n = 70
Prostate Cancer18F-rhPSMA-7.3
brief summary
To evaluate the effectiveness of a PSMA-PET scan in identifying recurrent prostate cancer after focal therapy
started
Oct 1, 2025
primary completion
Nov 1, 2028
completion
Nov 1, 2028
last updated
Mar 23, 2026
detailed description
PSMA is a protein that is highly expressed in prostate cancer cells, making it an excellent specific target for imaging with PET scans that can provide detailed information about the location, extent and aggressiveness of prostate cancer lesions. These scans have proven invaluable for identifying and characterizing prostate cancer, aiding in treatment planning, and Monitoring treatment response. It's true and fully utility in focal therapy for prostate cancer is unknown.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol